The most effective drug to treat acute ischemic stroke, tissue plasminogen activator (tPA), must be applied within three hours after symptom onset because of the risk of hemorrhage and other complications such as neurotoxicity. The anticancer drug imatinib (Gleevec) may help overcome these limitations by counteracting the ability of tPA to increase the permeability of the blood-brain barrier (pages 731–737).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
de la Ossa, N.P. et al. Neurology 70, 1238–1243 (2008).
Kulkens, S. & Hacke, W. Expert Rev. Neurother. 7, 783–788 (2007).
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333, 1581–1587 (1995).
Tsirka, S.E. et al. J. Neurosci. 17, 543–552 (1997).
Wang, Y.F. et al. Nat. Med. 4, 228–231 (1998).
Zhuo, M. et al. J. Neurosci. 20, 542–549 (2000).
Su, E.J. et al. Nat. Med. 14, 731–737 (2008).
Fredriksson, L., Li, H., Fieber, C., Li, X. & Eriksson, U. EMBO J. 23, 3793–3802 (2004).
Yepes, M. et al. J. Clin. Invest. 112, 1533–1540 (2003).
Nicole, O. et al. Nat. Med. 7, 59–64 (2001).
Breedveld, P., Beijnen, J.H. & Schellens, J.H. Trends Pharmacol. Sci. 27, 17–24 (2006).
Krupinski, J. et al. Stroke 28, 564–573 (1997).
Endres, M. et al. Cerebrovasc. Dis. 25, 268–278 (2008).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rieckmann, P. Imatinib buys time for brain after stroke. Nat Med 14, 712–713 (2008). https://doi.org/10.1038/nm0708-712
Issue Date:
DOI: https://doi.org/10.1038/nm0708-712
This article is cited by
-
The Efficiency of India's Patent Layering Regime – Section 3(d) from Scientific Terminology to Patenting Implications
IIC - International Review of Intellectual Property and Competition Law (2015)